• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

存在疫苗效力衰减情况下的疫苗效力评估:在霍乱疫苗中的应用

Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.

作者信息

Durham L K, Longini I M, Halloran M E, Clemens J D, Nizam A, Rao M

机构信息

Department of Biostatistics, The Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.

出版信息

Am J Epidemiol. 1998 May 15;147(10):948-59. doi: 10.1093/oxfordjournals.aje.a009385.

DOI:10.1093/oxfordjournals.aje.a009385
PMID:9596473
Abstract

The authors present a nonparametric method for estimating vaccine efficacy as a smooth function of time from vaccine trials. Use of the method requires a minimum of assumptions. Estimation is based on the smoothed case hazard rate ratio comparing the vaccinated with the unvaccinated. The estimation procedure allows investigators to assess time-varying changes in vaccine-induced protection, such as those produced by waning and boosting. The authors use the method to reanalyze data from a vaccine trial of two cholera vaccines in rural Bangladesh. This analysis reveals the differential protection and waning effects for the vaccines as a function of biotype and age.

摘要

作者提出了一种非参数方法,用于根据疫苗试验将疫苗效力估计为时间的平滑函数。该方法的使用需要最少的假设。估计基于比较接种疫苗者与未接种疫苗者的平滑病例风险率比。该估计程序使研究人员能够评估疫苗诱导的保护作用随时间的变化,例如由抗体衰减和加强产生的变化。作者使用该方法重新分析了孟加拉国农村地区两种霍乱疫苗的疫苗试验数据。该分析揭示了疫苗作为生物型和年龄函数的差异保护和衰减效应。

相似文献

1
Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.存在疫苗效力衰减情况下的疫苗效力评估:在霍乱疫苗中的应用
Am J Epidemiol. 1998 May 15;147(10):948-59. doi: 10.1093/oxfordjournals.aje.a009385.
2
The design and analysis of cholera vaccine trials: recent lessons from Bangladesh.霍乱疫苗试验的设计与分析:来自孟加拉国的近期经验教训。
Int J Epidemiol. 1993 Aug;22(4):724-30. doi: 10.1093/ije/22.4.724.
3
Field trial of oral cholera vaccines in Bangladesh.孟加拉国口服霍乱疫苗现场试验
Lancet. 1986 Jul 19;2(8499):124-7. doi: 10.1016/s0140-6736(86)91944-6.
4
Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.越南一种本地生产的口服霍乱灭活疫苗的现场试验。
Lancet. 1997 Jan 25;349(9047):231-5. doi: 10.1016/s0140-6736(96)06107-7.
5
Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines.在口服霍乱疫苗现场试验中,不参与作为不良健康结局的一个决定因素。
Am J Epidemiol. 1992 Apr 15;135(8):865-74. doi: 10.1093/oxfordjournals.aje.a116382.
6
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.孟加拉国口服霍乱疫苗现场试验:三年随访结果
Lancet. 1990 Feb 3;335(8684):270-3. doi: 10.1016/0140-6736(90)90080-o.
7
Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis.孟加拉国口服霍乱死疫苗产生的群体免疫:重新分析
Lancet. 2005;366(9479):44-9. doi: 10.1016/S0140-6736(05)66550-6.
8
Optimized oral cholera vaccine distribution strategies to minimize disease incidence: A mixed integer programming model and analysis of a Bangladesh scenario.优化口服霍乱疫苗分配策略以降低疾病发病率:孟加拉国情景的混合整数规划模型与分析
Vaccine. 2015 Nov 17;33(46):6218-23. doi: 10.1016/j.vaccine.2015.09.088. Epub 2015 Oct 11.
9
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.一种改良的口服霍乱全细胞灭活疫苗在印度的疗效与安全性:一项整群随机、双盲、安慰剂对照试验的中期分析
Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8.
10
Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from 2 years of follow-up of a randomised trial.单价型全细胞灭活口服霍乱疫苗的有效性:一项随机试验 2 年随访结果。
Lancet Infect Dis. 2018 Jun;18(6):666-674. doi: 10.1016/S1473-3099(18)30108-7. Epub 2018 Mar 14.

引用本文的文献

1
Competing Heterogeneities in Vaccine Effectiveness Estimation.疫苗效力估计中的竞争异质性
Vaccines (Basel). 2023 Aug 1;11(8):1312. doi: 10.3390/vaccines11081312.
2
Competing Heterogeneities in Vaccine Effectiveness Estimation.疫苗效力估计中的竞争异质性
ArXiv. 2023 May 12:arXiv:2305.01737v2.
3
Vibrio cholerae in rural and urban Bangladesh, findings from hospital-based surveillance, 2000-2021.孟加拉国农村和城市基于医院监测的霍乱弧菌,2000-2021 年的发现。
Sci Rep. 2023 Apr 19;13(1):6411. doi: 10.1038/s41598-023-33576-3.
4
The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01 vaccination and seasonal malaria chemoprevention versus either intervention given alone.季节性 RTS,S/AS01 疫苗接种联合季节性疟疾化学预防与单独使用任一干预措施相比,对临床疟疾的保护持续时间。
BMC Med. 2022 Oct 7;20(1):352. doi: 10.1186/s12916-022-02536-5.
5
Estimating Waning of Vaccine Effectiveness: A Simulation Study.估算疫苗效力衰减:一项模拟研究。
Clin Infect Dis. 2023 Feb 8;76(3):479-486. doi: 10.1093/cid/ciac725.
6
Comparing statistical methods for detecting and estimating waning efficacy of rotavirus vaccines in developing countries.比较发展中国家检测和估计轮状病毒疫苗效力衰减的统计方法。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4632-4635. doi: 10.1080/21645515.2021.1968738. Epub 2021 Oct 6.
7
Durability of protection after 5 doses of acellular pertussis vaccine among 5-9 year old children in King County, Washington.在华盛顿金县,5-9 岁儿童接种 5 剂无细胞百白破疫苗后的保护持久性。
Vaccine. 2021 Oct 1;39(41):6144-6150. doi: 10.1016/j.vaccine.2021.08.070. Epub 2021 Sep 4.
8
Assessing vaccine durability in randomized trials following placebo crossover.评估安慰剂交叉后随机试验中疫苗的持久性。
Stat Med. 2021 Nov 30;40(27):5983-6007. doi: 10.1002/sim.9001. Epub 2021 Apr 29.
9
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.安慰剂组接种疫苗后评估 COVID-19 疫苗效果持久性的延期接种设计。
Ann Intern Med. 2021 Aug;174(8):1118-1125. doi: 10.7326/M20-8149. Epub 2021 Apr 13.
10
Waning Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2015-2016 to 2018-2019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network.2015-2016 年至 2018-2019 年美国住院成人流感疫苗有效性网络:成人因流感相关住院的疫苗有效性逐渐降低。
Clin Infect Dis. 2021 Aug 16;73(4):726-729. doi: 10.1093/cid/ciab045.